Introduction
Thromboxane A2 (TX), a labile metabolite of arachidonic acid, is known to induce many biological actions-e.g., platelet aggregation and contraction and growth of vascular smooth muscle cells (VSMCs) (1, 2) -that are mediated via its specific membrane TX receptor (TXR), and plays an important role in the progression of atherosclerosis (3) . Moreacid (ATRA) intracellularly, which subsequently isomerizes to 9-cis retinoic acid (9cRA) (10) . Signal transduction of retinoids is mediated by two groups of nuclear receptors, retinoic acid receptors (RARs) and retinoid X receptors (RXRs), which usually form a heterodimer on DNA sequences termed RA-response elements (RAREs) for transactivation (10) . ATRA binds to and activates RARs, while 9cRA binds to and activates both RARs and RXRs (10) . Among these retinoid receptors, all 3 RAR isoforms (-α, -β, and -γ ) and 2 RXR isoforms (-α and -β ) are expressed in VSMCs (9) . Retinoids are reported to inhibit cell proliferation, migration, and neointima formation after vascular injury, and to induce cell differentiation and apoptosis in VSMCs (8, 9) , which may result in their anti-atherosclerotic effects. Moreover, these effects are known to be mediated, at least in part, via retinoid receptors (9) . Although TX systems are one of the factors promoting atherosclerosis, little is known regarding retinoids' actions against them. We therefore examined the effects of retinoids on TX-induced cell growth and TXR expression in VSMCs.
Methods

Plasmids
The following previously described chimeric constructs (5-7) were used: 989-luc (989-base pair (bp) 5 -flanking region (FL) and 184-bp 5 -untranslated region (UTR) of the rat TXR gene); 809-luc (809-bp 5 -FL and 5 -UTR); 489-luc (489-bp 5 -FL and 5 -UTR); 213-luc (213-bp 5 -FL and 5 -UTR); 78-luc (78-bp 5 -FL and 5 -UTR); 47-luc (47-bp 5 -FL and 5 -UTR); 39-luc (39-bp 5 -FL and 5 -UTR); 22-luc (22-bp 5 -FL and 5 -UTR); and 6-luc (6-bp 5 -FL and 5 -UTR). β-Galactosidase control plasmid in pCMV was purchased from Clontech (Palo Alto, USA). Human RAR-α expression plasmid in pCMX (11) (provided by Dr. K. Umesono, Kyoto University, Kyoto, Japan), mouse RXR-α expression plasmid in pcDNA1/Amp (7), and Sp1 in pCMSV (12) (provided by Dr. Y. Fujii, Tohoku University, Sendai, Japan) were used for in vitro translation.
H-Thymidine Incorporation
When rat VSMCs grown in 3.5 cm plates became 70% confluent, media were changed to serum-free MEM and incubated for 2 days. Then the cells were incubated for 24 h with 1 µCi/ml 3 H-thymidine (Amersham Biosciences, Buckinghamshire, UK) in serum-free MEM in the presence or absence of 1 µmol/l U-46619 (1) (a stable TX mimetic) (Cayman Chemical, Ann Arbor, USA), which was added alone or in combination with 1 µmol/l ATRA (Sigma, St. Louis, USA). In an experiment, ATRA was incubated with U-46619 during the last 8 h. The cells were washed twice with ice-cold PBS, incubated with 500 µl 5% trichloroacetic acid (TCA) for 30 min at 4 ºC, washed twice with 1 ml 5% TCA, and incubated with 400 µl 1 mol/l NaOH for 20 min at room temperature. After neutralization with 400 µl 1 mol/l HCl, the cell extracts were put into vials with 5 ml of scintillation solution and counted in a β-counter.
Semi-Quantitative Reverse Transcription (RT)-Polymerase Chain Reaction (PCR)
When cultured rat VSMCs became 70% confluent, the media were replaced with stripped medium (13) and were incubated for 5-6 h. The cells were then incubated with 1 µmol/l ATRA (Sigma) or 1 µmol/l 9cRA (Sigma) for 24 h, and their total RNAs were extracted using an RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The extracted RNAs (1 µg) were then subjected to RT-PCR using specific primers for rat TXR (5) and rat glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) (5) for 30 cycles simultaneously.
Transient Transfection Study/Luciferase Assay
When cultured rat VSMCs became 70% confluent, the media were replaced with stripped medium (13) and were incubated for 5-6 h. The cells were then transfected using lipofectin according to the manufacturer's instructions (GIBCO BRL, Gaithersburg, USA). Briefly, 1.2 µg reporter plasmid and 0.8 µg β-galactosidase control plasmid were mixed with 6 µl lipofectin per 3.5 cm plate. Twelve hours after transfection, the media were replaced with stripped medium and the cells were incubated for an additional 12 h. The cells were then incubated either with 1 µmol/l ATRA (Sigma), 1 µmol/l 9cRA (Sigma), or one of several concentrations of Ch55 (14) (an RAR-selective agonist), Am80 (14) (an RAR-selective agonist), HX630 (14) (an RXR-selective agonist), or PA024 (14) (an RXR-selective agonist) for 24 h (these 4 agonists were provided by Dr. H. Kagechika, University of Tokyo, Tokyo, Japan). After harvesting, the cell extracts were analyzed for both luciferase and β-galactosidase activities (7) to determine the expression of both genes. The transfection efficiency was normalized by the β-galactosidase expression.
Western Immunoblot Analyses
Western immunoblot analyses of VSMC nuclear extracts were performed as previously described (13) using either anti-RAR-α, anti-RAR-β, and anti-RAR-γ antibodies (15) (Santa Cruz Biotechnology, Santa Cruz, USA) or anti-RXR-α and anti-RXR-β antibodies (13) .
Electrophoretic Mobility Shift Assay (EMSA)
In vitro transcription/translation of human RAR-α mouse RXR-α, and Sp1 cDNA clones was performed using TNT TM kits (Promega, Madison, USA). In order to confirm the generation of these proteins, in vitro transcription/translation in the presence of 35 S-methionine was simultaneously per-formed, and the amounts of generated RAR-α and RXR-α proteins were confirmed to be equal by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Unprogrammed reticulocyte lysate was also generated simultaneously. EMSA was performed as described previously (13) . Briefly, 32 P-labeled double-stranded oligonucleotides containing the 47/ 7 region of the TXR gene promoter (CCGGCTGAGGGGCGAGGCCAGTGCAGGGGGTGGG GCTGGCG) (7) were incubated with several combinations of in vitro translated Sp1, RAR-α, or RXR-α for 30 min at room temperature, and then subjected to electrophoresis on 4% polyacrylamide gels. Total amounts of reticulocyte lysate in each lane were fixed to the same amounts by adding unprogrammed reticulocyte lysate.
Statistical Analyses
Statistical analyses of the transient transfection studies were performed by one-factor ANOVA using the program StatView 4.0 (ABACUS Concepts, Berkeley, USA).
Results
Effects of Retinoids on TX-induced 3 H-Thymidine Incorporation
We first examined the effects of retinoids on TX-induced VSMC proliferation as assessed by 3 H-thymidine incorporation. As shown in Fig. 1, 1 µmol/l TX mimetic U-46619 induced an approximately 160% increase (vs. the basal value) in 3 H-thymidine incorporation into VSMCs (lanes 1 and 3), which was in agreement with the result in our previous study (7) . When VSMCs were co-incubated with 1 µmol/l ATRA, the U-46619-stimulated increase in 3 H-thymidine incorporation was completely inhibited at 24 h (lane 5), but not at 8 h (lane 4) of culture. Incubation with ATRA alone for 24 h had little effect (lane 2). These data indicate that retinoids can significantly inhibit the TX-induced proliferation of VSMCs, and that this inhibition is probably mediated by a long-term effect that includes gene expression regulation, rather than by a short-term effect.
Effects of Retinoids on TXR mRNA Expression
We next examined the effects of retinoids on TXR mRNA expression in VSMCs. As shown in Fig. 2 , the expression of TXR mRNA was significantly decreased by treatment of VSMCs either with 1 µmol/l of ATRA (lane 2) or 9cRA (lane 3). These data indicate that retinoids negatively regu- late TXR mRNA expression, which may cause the inhibition of the TX-induced VSMC proliferation.
Effect of Retinoids on TXR Gene Promoter Activity
We next examined the effects of retinoids on TXR gene transcription. A luciferase chimeric construct containing the fulllength TXR gene promoter ( 989-luc) was transfected into VSMCs, and its luciferase activity was examined (Fig. 3A) . Treatment of transfected VSMCs either with 1 µmol/l of ATRA (lane 2) or 9cRA (lane 3) significantly suppressed the transcription of 989-luc. These data suggest that both ATRA and 9cRA suppress TXR expression at the gene transcription level.
Regarding retinoid receptors, ATRA binds to and activates RARs while 9cRA binds to and activates both RARs and RXRs (10) . We therefore used retinoid receptor-selective agonists (1 µmol/l each) in order to identify the receptor(s) involved in the TXR gene transcription suppression. As shown in Fig. 3A , the RAR-selective agonists Ch55 (lane 4) and Am80 (lane 5) significantly suppressed TXR gene transcription at almost the same level as ATRA (lane 2) and 9cRA (lane 3). In contrast, the RXR-selective agonists HX630 (lane 6) and PA024 (lane 7) suppressed the TXR gene transcription weakly. Dose-response analyses (Fig. 3B ) also demonstrated that the RAR-selective agonists Ch55 and Am80, but not the RXR-selective agonists HX630 and PA024, suppressed the transcription. These data suggest that RARs, rather than RXRs, are mainly involved in the transcription suppression. In order to confirm the expression of endogenous retinoid receptors in VSMCs, Western immunoblot analyses were performed. Consistent with the previous reports (9, 16) , endogenous protein expression of all 3 RAR isoforms (-α, -β, and -γ) and 2 RXR isoforms (-α and -β ) was observed (data not shown). These data strongly suggest that the TXR gene transcription suppression is mediated via an activation of endogenous RARs in VSMCs.
Identification of the Element(s) Responsible for the Transcription Suppression
In order to identify the element(s) responsible for the TXR gene transcription suppression, we next used several luciferase chimeric constructs containing deletion mutants of the TXR gene promoter ( 809-luc, 489-luc, 213-luc, 78-luc, 47-luc, 39-luc, 22-luc, and 6-luc). As shown in Fig. 4 , ATRA-mediated transcription suppression was observed in all constructs from 989-luc to 22-luc. However, ATRA did not affect the transcription of 6-luc (Fig.  4) , suggesting that the element between 22 and 7 comprised of a GC-box related sequence (5, 7) was the element responsible for the TXR gene transcription suppression.
Inhibition of Sp1 Binding to DNA by RAR
We next examined protein-DNA interactions on the 47/ 7 region of the TXR gene promoter (Fig. 5 ). When 32 P-labeled 47/ 7 region oligonucleotides were incubated with in vitro translated RAR-α and/or RXR-α, formation of a protein-DNA complex was not observed (lanes 1-3) . These results suggest that neither RAR nor RXR binds to the 47/ 7 region either as a homodimer or as a RAR/RXR heterodimer, which would be consistent with the absence of RAREs within the region (5, 7) . On the other hand, incubation with in vitro translated Sp1 and (lanes 4-9), RAR-α (lanes 1, 3, and  9 ), or RXR-α (lanes 2, 3, and 7) . In lane 8, 1 µl of RAR-α was used. In lane 6, 1 µl of RXR-α was used. Sp1-DNA complexes are indicated by arrows (Sp1). The total amount of reticulocyte lysate in each lane was fixed to 6 µl by adding unprogrammed reticulocyte lysate. complex (lane 4, designated "Sp1" and indicated by an arrow), consistent with our previous observation (7). Regarding the Sp1-DNA complex, in our previous study using EMSA with mutated oligonucleotides and antibody supershift experiments, we demonstrated that Sp1 binds only to the 22/ 7 GC-box related sequence within the 47/ 7 region, and that the endogenous VSMC proteins bound to the sequence are mainly Sp1 (7) . Therefore, the observed Sp1-DNA complex in Fig. 5 should also be formed on the 22/ 7 GC-box related sequence. We next examined the effects of RAR or RXR on the Sp1-DNA complex. When increasing amounts (from 1 to 3 µl) of RXR-α were incubated in the presence of Sp1, formation of the Sp1-DNA complex (lane 5, designated "Sp1" and indicated by an arrow) was not affected (lanes 6 and 7). In contrast, incubation with increasing amounts (1 to 3 µl) of RAR-α in the presence of Sp1 significantly decreased the formation of the Sp1-DNA complex (lanes 8 and 9) in correspondence with the amount added. These data suggest that RAR, but not RXR, inhibits formation of the Sp1-DNA complex on the 22/ 7 GC-box related sequence.
Discussion
TX-induced VSMC proliferation was inhibited by retinoids. Since TXR mRNA expression in VSMCs was also decreased by retinoids, the inhibition of TX-induced cell proliferation may have been due to the decrease in TXR expression. Moreover, the decrease in TXR expression was shown to be due to TXR gene transcription suppression by activated RAR. Deletion analyses and EMSA demonstrated that the TXR gene transcription suppression was mediated through the 22/ 7 GC-box related sequence, most likely by RARmediated inhibition of Sp1 binding to the DNA element. Since Sp1, a ubiquitously expressed transcription factor, has recently been shown to be involved in cell growth, including angiogenesis and tumorigenesis (17) , it is reasonable that the gene transcription suppression of TXR, which is involved in the growth of VSMCs, is mediated by Sp1 inhibition.
The mechanism by which RAR inhibits Sp1 binding to DNA remains unclear. Recently, several studies have demonstrated a physical interaction between RAR and Sp1 (18) (19) (20) . It is therefore possible that our observation regarding the inhibition of Sp1 binding to the 22/ 7 GC-box related sequence by RAR may be mediated by a protein-protein interaction between RAR and Sp1. Interestingly, previously reported TXR gene transcription suppression by PPAR-γ, which was mediated through the same 22/ 7 GC-box related sequence, was due to the inhibition of Sp1 binding to the DNA element by a protein-protein interaction between PPAR-γ and Sp1 (7) . Both PPAR-γ and RAR may thus suppress TXR gene transcription by the same mechanism through Sp1 inhibition. The combined use of retinoids and lower concentrations of PPAR-γ ligands may therefore be beneficial in terms of reducing the respective side effects. A similar RAR-mediated inhibition of DNA binding was previously reported in AP-1 (21) . Since, in the previous studies, the RAR-Sp1 physical interactions were related to the enhancement of Sp1-mediated transcription (18) (19) (20) , this may be the first report describing the transcription suppression through Sp1 inhibition by RAR.
The anti-proliferative effects of retinoids in VSMCs have recently received much attention (8, 9) . Retinoids inhibit VSMC proliferation by modulating cell cycle regulators, such as by elevating p27 or inhibiting cyclin D, which results in the inhibition of retinoblastoma protein phosphorylation (22, 23) . Retinoids downregulate angiotensin II (AII) type 1 receptor expression in VSMCs, resulting in the inhibition of AII actions on VSMCs (24, 25) . Retinoids have also been reported to induce apoptosis in VSMCs (26, 27) . Incubation of multipotential P19 embryonal carcinoma cells with retinoids induces differentiation of VSMCs through the induction of α-smooth muscle actin (28, 29) . Moreover, RA inhibits the production of several matrix metalloproteinases, and this inhibition may suppress the migration of VSMCs (30, 31) . Neointima formation after endothelial injury has also been shown to be inhibited by RA treatment in vivo (27, 32, 33) . Taken together, these results indicate that retinoids exert anti-atherosclerotic effects in VSMCs. Since TX is known to enhance the proliferative response to vascular injury in vivo (4), inhibition of TXR expression may play an important role in the in vivo inhibition of neointima formation by retinoids. Our study therefore provided a novel anti-atherosclerotic action of retinoids in VSMCs.
In conclusion, we have shown that retinoids suppress TXR gene expression at the transcription level by activating RAR, and inhibit TX-induced cell proliferation in VSMCs. Since the development of new synthetic retinoids with higher activity and lower toxicity is already rapidly underway (14) and several retinoids have already been approved for clinical use (9) , retinoids are expected to provide a novel therapeutic treatment against proliferative vascular diseases.
